New Study Shows Cannabis Could Help with Fibromyalgia Symptoms

11th March 2020
By Emily Ledger

Cannabis has been used medicinally to help manage pain for thousands of years – before prohibition began. However, the illegal status of cannabis in developed nations around the world – which coincided with the heights of scientific development and research – has meant that there is little clinical evidence of how medical cannabis can help with a whole range of conditions, including Fibromyalgia.

Fibromyalgia is the second most common rheumatological  It is estimated that 3-6% of the world’s population suffers from Fibromyalgia – a chronic condition characterised by prolonged pain, soreness, and fatigue. In fact, it affects around 10 million people in the US alone. Yet treatment for the condition remains fairly unreliable, with many patients being prescribed highly addictive opiates.

There have been a number of studies assessing the efficacy of cannabis in treating chronic pain. However, few of these studies focused specifically on Fibromyalgia. Yet, a new study, published in Clinical and Experimental  Rheumatology, has yielded results that may support the use of medical cannabis in Fibromyalgia.

The Study

Researchers from the Luigi Sacco University Hospital in Milan, Italy, recruited 102 Fibromyalgia patients for their study into the efficacy of medical cannabis. The participants received two cannabis oils (one high-THC and one balanced) and monitored for a period of six months.

As well as monitoring patients’ Fibromyalgia severity, using a number of official medical scales, patients were also given the option to reduce or stop their existing analgesic therapies. 66 patients continued with the trial for the full six month period. Dropouts were reportedly down to numerous factors, including adverse effects (6), lack of benefit (3), and continued treatment at another centre (10). Others were lost for unreported reasons.

The Results

The study assessed the impact of medical cannabis on various symptoms of Fibromyalgia: Fatigue, sleep quality, anxiety, depression, and pain.

Results showed significant clinical improvement in some of these symptoms. For example, 44 % of patients reported a significant improvement in sleep quality and Fibromyalgia Impact Questionnaire Revised (FIQR) scores improved in 33% of patients. In addition, patients also showed moderate improvements in anxiety (42.4%) and depression (50%).

In relation to pain as a result of Fibromyalgia, the study showed that 31 of the 66 (47%) participants reduced or ceased their other analgesic treatments.

However, results also showed worsening of some symptoms. This was mainly seen in fatigue scores as identified by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score. Researchers write that 54.5% of patients experienced clinical worsening of this symptom.

Interesting Insights

The majority of people who suffer from Fibromyalgia are women (75-90%). This was reflected in the study, with 91% of participants being female. Researchers also noted that a majority of participants were also moderately overweight (40.9%) or obese (13.6%). This surprisingly seemed to play a significant role in clinical improvement.

The report claims that BMI score was the only co-variate which explained an improvement of 30% or more in the Fibromyalgia Impact Questionnaire score.

Findings from the study show that medical cannabis could be a relatively effective treatment option for Fibromyalgia. Researchers who work on the study have also backed the findings:

MCT [Medical Cannabis Treatment] has proved to be a much safer adjunct than opioid treatment, which is associated with a high risk/benefit ratio and is not effective in treating FM [fibromyalgia] (24); furthermore, MCT does not have any substantial addictive properties in terms of dose escalation or withdrawal syndrome (25-26).”


Related Stories

Would you like to know the results of our polls? Please complete the data request form by clicking here.

About the Author

Emily Ledger
Prior to joining the team at Canex, Emily studied Journalism at Sheffield Hallam University for three years. During her studies, she specialised in magazine and feature writing and went on to contribute to both the content and design departments at a local magazine. Emily is now the Head of Content at Canex where she has been both curating and contributing articles and content since the launch of the website.

Enjoying this article?

Join the thousands of subscribers who stay ahead of the game.

Advertise on Canex

Reach thousands of customers, as well as industry leaders and manufacturers
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on whatsapp

Subscribe to our newsletter

All the latest CBD news & updates, direct to your inbox
By submitting this form, you are giving Canex permission to contact you directly via email or telephone. You can opt out at any stage, and your contact data will never be shared with any 3rd party without your explicit consent. Our Privacy Policy.

Keeping subscribers up-to-date with news & insight within the CBD industry. From regulation and legislation reforms, industry updates and guides through the ongoing studies of the substance; to product news, reviews and guides.

© 2020 | Canex Group Ltd | All Rights Are Reserved